Cancerify Logo
Log inSign up
Back to clinical trials
RecruitingObservational

Cognitive Aging in Older Long-term Breast Cancer Survivors

NCT ID: NCT06334354Sponsor: Memorial Sloan Kettering Cancer CenterLast updated: 2026-05-14

Summary

The purpose of this study is to look at how differences in cognitive (mental) function develop over time in breast cancer survivors compared to volunteers without a history of cancer (healthy volunteers). Both cancer survivors and healthy volunteers (who are the same age as the cancer survivors) will participate in this study so the researchers can compare the results of neurocognitive testing (which looks at memory, attention, and information processing) on each group of participants.

Arms & interventions

  • OtherAssessments

    Sociodemographics, Deficit Accumulation Questionnaires, Remote Cognitive Assessment, Deficit Accumulation Questionnaires,Remote Cognitive Assessment

  • OtherAssessment (Survivors Only)

    \*Tumor/Treatment Variables (Survivors Only)

  • OtherAPOE and DNA Isolation

    Biospecimens procurement and processing

Outcome measures

Primary

  • examine cognitive effects

    of remote cancer diagnosis and treatment and potential association with increased/accelerated deficit accumulation in older survivors.The primary outcome is cognitive performance, as measured by CogSuite aggregate intra-individual variability, the average intra-individual variability across the subtests. Cognition will be assessed using the CogSuite battery of five subtests: 1) Attention Network Test; 2) Mental Rotation; 3) Stop Signal Delay; 4) N-back; and 5) Psychomotor Speed measures.

    Time frame: within 45 days of participant consent

Secondary

  • measure levels of smoking exposure

    Time frame: within 45 days of participant consent

Eligibility criteria

Sex: FemaleAge: 60 Years to 80 YearsHealthy volunteers: Yes
Inclusion Criteria: All Participants: * Per medical record and/or self-report, identifies as female * Per medical record and/or self-report, currently age 60-80 * Per self-report, has access to a computer and internet connectivity * Score of \<11 on Blessed Orientation-Memory-Concentration Test (BOMC) * As per medical record or self-report, if currently taking psychoactive medications (including but not limited to antidepressants and anxiolytics), dose must have been stable at least two months prior to enrollment. * English fluent (as per self-report, fluency of "well" or "very well", and having a reasonable comprehension of the study conversation in the opinion of the research staff)\*\* Breast Cancer Survivors: * Per medical record and/or self-report, history of stage 0-3 breast cancer diagnosed between 50-60 years of age * Per medical record and/or self-report, no evidence of disease (NED) Non-Cancer Controls: * Per self-report, no history of breast cancer * Language verification: For both survivors and controls, prior to enrollment, all will be asked the following two questions by a CRC to verify English fluency necessary for participation in the study: 1. How well do you speak English? (must respond "Well" or "Very well" when given the choices of Very well, Well, Not well, Not at all, Don't know, or Refused) 2. What is your preferred language for healthcare? (must respond English) Exclusion Criteria: All participants: * As per medical record or self-report, diagnosis of neurodegenerative disorder that affects cognitive function (e.g. Alzheimer's disease, Parkinson's disease, Multiple Sclerosis, Dementia, Seizure Disorders, etc.) * As per medical record or self-report, history of stroke or head injury resulting in a structural lesion on neuropsych imaging, persistent cognitive difficulties impacting work or daily life, or required cognitive rehabilitation * As per medical record or self-report, a diagnosis of a major Axis I psychiatric disorder including Schizophrenia Spectrum Disorder, substance use disorder, Bipolar Disorder or Schizotypal personality disorder. Schizophrenia Spectrum Disorders include Schizophrenia, Schizophreniform disorder, Schizoaffective disorder, Delusional disorder, Brief psychotic disorder, and Attenuated Psychotic Disorder. * As per medical record or self-report, visual or auditory impairment that would preclude ability to complete the assessments (e.g. history of significant macular degeneration or being unable to correct hearing with hearing aids) * As per medical record or self-report, use of methotrexate (Amethopterin, Rhematrex, Trexall) or rituximab (Rituxin) for rheumatoid arthritis, psoriasis or Crohn's disease, or cyclophosphamide (Cytoxan, Neosar) for lupus. * As per medical record or self-report, participation in a conflicting (overlapping neurocognitive assessments) research study (i.e. MSK 18-294) Breast Cancer Survivors: * As per medical record or self-report, history of cancer recurrence * As per medical record or self-report, any history of another cancer except nonmelanoma skin cancer or first breast cancer (a secondary breast cancer is exclusionary) * As per medical record or self-report, breast cancer only treated with surgery Non-Cancer Controls: * As per medical record or self-report, history of treatment using radiation, chemotherapy, and/or Tamoxifen or Aromatase-inhibitors * As per medical record or self-report, any history of cancer except non-melanoma skin cancer

Study locations (7)

Memorial Sloan Kettering Basking Ridge (All Protocol Activities)

Basking Ridge, New Jersey, 07920

Recruiting
James Root, PhD · Contact

Memorial Sloan Kettering Monmouth (All protocol activities)

Middletown, New Jersey, 07748

Recruiting
James Root, PhD · Contact

Memorial Sloan Kettering Bergen (All Protocol Activities)

Montvale, New Jersey, 07645

Recruiting
James Root, PhD · Contact

Memorial Sloan Kettering Suffolk - Commack (All Protocol Activities)

Commack, New York, 11725

Recruiting
James Root, PhD · Contact

Memorial Sloan Kettering Westchester (All Protocol Activities)

Harrison, New York, 10604

Recruiting
James Root, PhD · Contact

Memorial Sloan Kettering Cancer Center

New York, New York, 10065

Recruiting
James Root, PhD · Contact
Denise Correa, PhD · Contact
James Root, PhD · Principal Investigator

Memorial Sloan Kettering Nassau (All Protocol Activities)

Uniondale, New York, 11553

Recruiting
James Root, PhD · Contact